IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo
Latest Information Update: 05 May 2022
At a glance
- Drugs IMCY-0098 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms IMCY-T1D-002
- Sponsors ImCyse
Most Recent Events
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 14 Jan 2020 Status changed from recruiting to completed.
- 10 Dec 2019 New trial record